Aim immunotech announces charles lapp, md, as a consulting medical officer for its me/cfs and long covid programs

Ocala, fla., april 15, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim”) today announced that charles lapp, md, is joining the company to help lead its efforts to develop ampligen (rintatolimod) as a potential treatment for myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) and long covid.
AIM Ratings Summary
AIM Quant Ranking